Do GLP‑1 patches, drops or supplements work? What Health Canada says
Why no patch, drop or supplement is an approved GLP‑1 medicine in Canada, what the national obesity guideline says about weight-loss products, and how to check a product and report an ad.
Written for Canada, from Canadian sources.
No. Every GLP‑1 medicine authorized in Canada is an injection or a tablet, and none is a patch, drop or supplement. Canada’s obesity guideline does not recommend over-the-counter weight-loss products, because none studied for more than 12 weeks produced meaningful weight loss. Some “GLP‑1” drop ads have used fake endorsements.
Key takeaways
- Every semaglutide, tirzepatide, liraglutide and dulaglutide product in Health Canada’s Drug Product Database is a prescription injection or tablet; none is a patch or drop.1
- Health Canada’s January 2026 advisory says authorized GLP‑1 drugs come “in injectable formats or as oral tablets”, and warns of fake endorsements in ads.2
- Canada’s obesity guideline says none of the commercial weight-loss products studied for more than 12 weeks produced clinically meaningful weight loss.3
- Diabetes Canada received more than 300 reports in 4 months of misleading ads using its logo, including for “GLP‑1 oral drops”, CBC News reported in May 2025.4
- You can check a natural product’s licence number in Health Canada’s database and report a misleading ad to Health Canada.5,6
- GLP‑1 medicines are prescription drugs in Canada.1 We describe types of products, not brands, and we don’t link to any seller.
- Canadian law bans advertising any drug to the general public as a treatment, preventative or cure for obesity or diabetes.7 This page is information, not an ad, and nothing here is for sale.
On this page
What are “GLP‑1” patches, drops and supplements?
Products sold online with “GLP‑1” in the name or the ads, such as skin patches, drops taken by mouth and other supplements. They borrow the name of prescription medicines.4
GLP‑1 medicines such as Ozempic, Wegovy and Zepbound are prescription drugs that copy a gut hormone.1,8 CBC News reported in 2025 that misleading ads were promoting products that “mimic the names” of these medicines, including “GLP‑1 oral drops”.4
A McGill physician told CBC there are no drops or patches that give a similar effect to the prescription medicines.4
Is any GLP‑1 patch or drop approved in Canada?
No. On 14 October 2026, every GLP‑1 product in Health Canada’s Drug Product Database was a prescription injection under the skin or a tablet.1
Health Canada’s 2026 advisory on fake GLP‑1s describes the authorized drugs as coming “in injectable formats or as oral tablets”.2 The only tablets are Rybelsus, for type 2 diabetes.1,9
A natural health product can carry an eight-digit licence number (NPN) from Health Canada.3,5 The guideline’s authors note that many weight-loss supplements carry one; a licence number doesn’t make a product a GLP‑1 medicine.3
Do weight-loss supplements work?
Canada’s obesity guideline found no proof. None of the weight-loss products studied in randomized trials lasting more than 12 weeks produced clinically meaningful weight loss.3
Its recommendation: “We do not recommend the use of over-the-counter commercial weight loss products for obesity management, owing to lack of evidence.”3
Some supplements also hide drugs. The chapter says weight-loss supplements “have been found to contain prescription anti-obesity medications” and are often the subject of Health Canada recalls. It cites a study of US supplements that found more than 700 with unlabelled drug ingredients.3
Build your own list before an appointment. Free, no sign-up.
How do the ads mislead people?
Many use logos they have no right to. Diabetes Canada received more than 300 reports in 4 months about ads carrying its logo, CBC reported in May 2025.4
Logos of Obesity Canada and Health Canada also appeared on products. Health Canada told CBC its logo “should never appear on health or consumer products as a sign of endorsement or approval”.4 Its 2026 advisory says some ads “misuse official Health Canada logos and display fake endorsements”.2
The guideline lists warning signs for commercial weight-loss programs, and they fit these ads too. Be wary of anything that promises:3
- weight loss without diet or exercise;
- weight loss while eating as much as you want;
- loss from one part of the body;
- very fast loss, such as 30 pounds in 30 days;
- before-and-after photos or endorsements that seem too good to be true.
What should you do if you bought one?
Check what it is, and report it. Health Canada says selling unauthorized health products, or making false claims to treat illness, is illegal in Canada.4
- Check it. Search the NPN in the Licensed Natural Health Products Database, or a DIN in the Drug Product Database.5,2
- Report the ad. Health Canada takes complaints about health product advertising online or at [email protected].6
- Report a side effect. “Anyone can report a side effect” to Health Canada.10
- If you have diabetes, don’t replace a prescribed medicine with one of these. A physician quoted by CBC worried they could delay proper care.4
For fake pens and “research peptides”, see how to spot fake Ozempic or research-peptide GLP‑1s.
Questions people ask
Do GLP-1 patches work?
There is no evidence they do. No GLP‑1 patch is authorized in Canada, and Canada’s obesity guideline found no over-the-counter weight-loss product that produced meaningful weight loss in trials over 12 weeks.1,3
Are GLP-1 drops approved by Health Canada?
No. Every GLP‑1 medicine authorized in Canada is a prescription injection or tablet.1,2
Is there a natural GLP-1 supplement?
No supplement is an authorized GLP‑1 medicine. The guideline does not recommend over-the-counter weight-loss products, owing to lack of evidence.1,3
How can I check if a product is approved in Canada?
Look for an eight-digit DIN and search it in the Drug Product Database, or an NPN in the Licensed Natural Health Products Database.2,5
Where do I report a misleading GLP-1 ad?
Health Canada takes advertising complaints online or at [email protected].6
How we researched this
We searched Health Canada’s Drug Product Database for every semaglutide, tirzepatide, liraglutide and dulaglutide product on 14 October 2026, and read Health Canada’s January 2026 advisory, the commercial-products chapter of Canada’s adult obesity guideline and CBC News’s May 2025 report.
We describe types of products, not brands, even where a brand was named in our sources.
Before you move on
- A real GLP‑1 medicine needs a prescription and has a DIN.
- No patch, drop or supplement is an authorized GLP‑1.
- Ignore ads with official logos or celebrity endorsements.
- Report misleading ads and any side effects to Health Canada.
- Never swap a prescribed diabetes medicine for a supplement.
More from the Canada blog
The monthly Canada update
An independent guide to GLP‑1 medicines. We don’t sell medicines, take drug-company money, earn commissions or link to any provider. Once a month: Health Canada approvals, recalls, provincial coverage changes and official prices. How we write
Sources
- Health Canada. Drug Product Database: product records, schedule, route and status for every semaglutide, tirzepatide, liraglutide and dulaglutide product (all on the “Prescription” schedule; all subcutaneous injections or oral tablets; for example Sevmia “Approved”, not marketed; first generic semaglutide marketed 6 May 2026). Searched 14 October 2026. Link
- Health Canada. Thinking about buying GLP-1 drugs like Ozempic or Mounjaro? Beware of fake or unauthorized products. Advisory RA-81518, 21 January 2026 (authorized products come “in injectable formats or as oral tablets”; websites and ads “misuse official Health Canada logos and display fake endorsements”; check the eight-digit DIN; report suspected counterfeit and unauthorized products). Link
- Langlois MF, Freedhoff Y, Morin MP. Canadian Adult Obesity Clinical Practice Guidelines: Commercial Products and Programs in Obesity Management. Obesity Canada, Version 1, 11 June 2020 (recommendation 3: “We do not recommend the use of over-the-counter commercial weight loss products for obesity management, owing to lack of evidence”; supplements “often the subject of Health Canada’s recall and safety alerts”). PDF
- Zafar A. Diabetes Canada stresses it doesn’t endorse medical products after ads suggest otherwise. CBC News, 30 May 2025, updated 3 June 2025 (more than 300 reports in four months; ads for “GLP-1 oral drops”; a McGill physician: no drops or patches give a similar effect; Health Canada: products not authorized, logo use not permitted, investigating). Link
- Health Canada. Licensed Natural Health Products Database (search a product’s eight-digit NPN or DIN-HM). Checked 14 October 2026. Link
- Health Canada. Health product advertising incidents: how to report a complaint (online form, or [email protected]). Modified 18 June 2025, checked 14 October 2026. Link
- Food and Drugs Act (R.S.C., 1985, c. F-27), section 3(1): “No person shall advertise any food, drug, cosmetic or device to the general public as a treatment, preventative or cure for any of the diseases … referred to in Schedule A.1”; Schedule A.1 lists diabetes and obesity. Justice Laws Website. Checked 14 October 2026. Link
- Novo Nordisk Canada. Wegovy (semaglutide injection) Product Monograph, 2 October 2026 (indications; dose escalation 0.25, 0.5, 1, 1.7 mg every 4 weeks to 2.4 mg; reassess after 12 weeks on the maintenance dose; STEP 1–3 results; Table 4: nausea 44% vs 16% on placebo; perioperative aspiration warning). PDF
- Novo Nordisk Canada. Rybelsus (semaglutide tablets) Product Monograph, 13 July 2026 (type 2 diabetes; 3 mg for 30 days, then 7 mg, then 14 mg if needed, or 1.5, 4 and 9 mg in the newer tablets; empty stomach, at least 30 minutes before food, with no more than 120 mL of water; PIONEER 1 results; Table 3: nausea 11.0% on 7 mg and 19.7% on 14 mg vs 6.4% on placebo; diabetic retinopathy events 4.2% vs 3.8% in pooled trials, and temporary worsening with rapid improvement in glucose; about 1–2% absolute bioavailability; SNAC absorption enhancer; missed dose skipped; aspiration warning). PDF
- Health Canada. Adverse reaction and medical device problem reporting (“Anyone can report a side effect to a health or cannabis product”). Checked 14 October 2026. Link
Last checked 14 Oct 2026 · Next review due 14 Apr 2027 · Report an error
How this page was made. Written by the GLP Guidebook team from the sources above. Prices are official list, formulary or maker-submitted prices, never a pharmacy, clinic, savings-card or coupon price. Figures marked as our arithmetic are worked out from those sources. It’s general information, not medical advice, and not an advertisement for any medicine. Talk to your family doctor, nurse practitioner or pharmacist before starting, stopping or changing any medicine. We don’t sell, prescribe or recommend any brand or provider. How we write